



ANALYSIS OF TUMOUR VASCULARIZATION BY MICROVESSEL DENSITY AND ITS PROGNOSTIC SIGNIFICANCE IN SURFACE EPITHELIAL OVARIAN NEOPLASMS

Pathology

Dr. Bhanupriya Kakarala*

Consultant Pathologist, Medall Health Care, Vijayawada *Corresponding Author

Dr. Sana Fatima

Assitant Professor, Department of Pathology, Bowring & Lady Curzon Medical College, Bangalore

Dr. Hemalatha Surupanga

Consultant Pathologist, Trinity Fertility sevices, Hyderabad

ABSTRACT

Ovarian malignancy is one of the most common cancers contributing to significant morbidity and mortality. Tumour vascularization is critical to growth and metastasis of the tumour determining the course of disease. Microvessel density is a reliable indicator of degree of vascularization in a tumour and can be used as a parameter to compare aggressiveness. The purpose of this study was to evaluate the degree of tumour vascularization across a spectrum of surface epithelial ovarian tumours by calculating microvessel density. Immunohistochemistry was used to identify CD34 and quantify the microvessels observed. Our study revealed that malignant ovarian tumours have a higher microvessel density as compared to benign and borderline tumours. This finding is significant in context of treatment of advanced ovarian cancers by anti-angiogenic drugs to improve survival rates. Hence, microvessel density is an important prognostic factor in ovarian malignancy and can be used to monitor treatment using novel targeted therapy.

KEYWORDS

Ovarian carcinoma, Surface epithelial ovarian tumours, Tumour vascularization, CD34, Microvessel density.

INTRODUCTION

Ovarian carcinomas account for 3% of all cancers in females.¹ Ovarian carcinomas represent sixth most common female cancers and fourth leading cause of death due to cancers in women. Surface epithelial tumours are commonest variety of ovarian tumours followed by germ cell tumours.²

Epithelial ovarian cancers originate from normal ovarian surface epithelium or from inclusion cysts arising from surface epithelium.³ Recent evidence shows that high grade serous carcinoma arises from fallopian tube.⁴ Due to its insidious onset and paucity of symptoms, most patients present with advanced disease and 5 year survival rates are approximately 20%.⁵

Angiogenesis is a critical factor in tumour growth and metastasis because tumour proliferation is severely limited by the nutrient supply to proliferating cells.⁶ Hence tumorigenesis of malignant neoplasms is associated with extensive neovascularization.

Analysis of tumour vascularization by microvessel density and its prognostic significance has been evaluated in many tumours in earlier studies by Toi M et al, Weidner et al, Macchiarini P et al.⁷⁻¹² But there is a paucity of literature regarding characteristics of tumour vascularization in ovarian surface epithelial tumours. Hence the present study aims to evaluate microvessel density in ovarian surface epithelial tumours by using Immunohistochemistry.

CD34 is a cell surface protein expressed on endothelial cells. Upregulation of CD34 is associated with increased neovascularization during tumour development.¹³ In this study we have evaluated CD34 by antibodies to it using Immunohistochemistry. The purpose of this study was to evaluate the microvessel density in ovarian surface epithelial tumours and to study the difference in angiogenesis between benign and malignant tumours.

Studies have shown that antiangiogenic agents have an important role in treatment of ovarian cancer,¹⁴ and the most promising group of drugs are anti-VEGF drugs especially Bevacizumab.¹⁵ Recent advances in treatment have resulted in improvement in 5 year survival in patients with epithelial ovarian cancer.¹⁶ The greatest success in epithelial ovarian cancer has come from targeting angiogenesis.^{17,18,19}

MATERIALS & METHODS

This cross-sectional, retrospective study was performed at Gandhi Medical College, Secunderabad in the state of Telangana, India. The study was performed in the Department of Pathology from June 2015 to July 2017. All specimens of ovarian surface epithelial tumours with

adequate clinical history were included and other ovarian tumours were excluded from the study. The specimens were fixed in 10% formalin for 24 hours and then meticulously grossed. Representative bits were taken from the specimens and submitted for processing. The tissue bits were routinely processed and sections of 3-4 micron thickness were cut and stained with Haematoxylin and Eosin stains. The sections were then studied under microscopy and the results were recorded. Immunohistochemistry was done using Dako antibody to CD34.

Microvessel Density was calculated from CD34 stained sections by using the method proposed by Weidner et al.²⁰ In each section, three most vascular areas were chosen using low power field (10X)- HOTSPOTS. Number of microvessels in each hotspot was counted using high power field (40X) and average of three hotspots was recorded. Brown staining of endothelial cells, separated from adjacent microvessels, connective tissue and tumour cells was considered as single countable microvessel.¹³ Counts were expressed as total number of microvessels per hpf40X (0.196mm²). This data was referred to as Microvessel Density count (MVD). MVD was calculated for all the tumours and compared between benign and malignant tumours. P value was calculated using student t test. This study was approved by the institutional Human Ethics Committee.




Figure 1: IHC Stain- CD34 - 10X- serous carcinoma showing Hotspot




Figure 2: IHC Stain - CD34 - 40X - Seros carcinoma. Large lumen

vessels are excluded. Few microvessels which can be counted are shown by arrows

RESULTS

Out of the 100 epithelial ovarian tumours studied, the youngest age at diagnosis was 29 years and the oldest was 65 years. Our study revealed that of the 100 cases, 62 were benign, 8 were borderline and 30 were malignant. 56 of the tumours were classified as serous, 40 were classified as mucinous and 4 were determined to be Brenner tumours.

Table No 1: Age Distribution

Age	Number of Patients
20-29	01
30-39	11
40-49	56
50-59	28
60-69	04
Total	100 Cases

Table No 2: Histomorphological Distribution of Surface Epithelial Tumours of Ovary

Type of Tumour	Benign n= 62 Cases (62%)	Borderline n= 8 Cases (8%)	Malignant n = 30 Cases (30%)
SEROUS TUMOURS n=56(56%)	36	04	16
MUCINOUS TUMOURS n=40(40%)	24	04	12
BRENNER TUMOURS N=4(4%)	02	--	02

Table No 3: Frequency Distribution of Surface Epithelial Tumours of Ovary

Histomorphological Type	Number of Cases (n=100)
Serous Cystadenoma	28
Serous Adenofibroma	08
Serous Borderline Tumour	04
Serous Carcinoma	16
Mucinous Cystadenoma	24
Mucinous Borderline Tumour	04
Mucinous Carcinoma	12
Brenner Tumour	02
Malignant Brenner Tumour	02




Figure No 3: H & E Stain- 40X - Serous Cystadenoma showing cyst wall lined by cuboidal epithelium




Figure No 4: H & E Stain- 40X - Serous Carcinoma showing papillae with fibrovascular core lined by malignant cells




Figure No 5: H & E Stain- 40X - Mucinous Cystadenoma showing cyst wall lined by simple mucinous epithelium




Figure No 6: H & E Stain- 40X - Mucinous Carcinoma showing pools of mucin




Figure No 7: H&E Stain-40X- Benign Brenner tumour showing transitional epithelium with coffee bean nuclei




Figure No 8: H&E Stain-40X- Malignant Brenner tumour showing malignant transitional epithelium with focus of benign island




Figure No 9: IHC Stain- CD 34- 40X- Benign mucinous cystadenoma showing low microvessel density




Figure No 10: IHC stain - CD 34- 40x- Benign serous cystadenoma showing low microvessel density




Figure No 11: IHC Stain- CD 34 –10X- serous carcinoma showing hot spot




Figure No 12: IHC Stain-CD34- 40X- Mucinous carcinoma showing high microvessel density

Table No 4: Micro Vessel Density of Benign ovarian surface epithelial Tumours

Benign Tumours	Number of Cases	Mean MVD / HPF (SD)
Serous Cystadenomas	36	4.50
Mucinous Cystadenoma	24	4.33
Brenners	02	06
Total	62	4.48(0.99)

NOTE: Mean microvessel density per high power field of benign ovarian surface epithelial tumours is 4.48 ± 0.99

Table No 5: Micro Vessel Density of Borderline Ovarian surface epithelial Tumours

Borderline Tumours	Number of Cases	Mean MVD/HPF
Serous Borderline Tumour	04	7.5
Mucinous Borderline Tumour	04	7.5
Total	08	7.5

NOTE: Mean micro vessel density per high power field of borderline ovarian surface epithelial tumours is 7.5

Table No 6: Micro Vessel Density of Malignant ovarian surface epithelial tumours

Malignant Tumours	Number of cases	Mean MVD /HPF (SD)
Serous Carcinoma	16	17.37
Mucinous Carcinoma	12	16.33
Malignant Brenner Tumour	02	11
Total	30	16.53(2.36)

NOTE: Mean Micro vessel density per high power field of malignant ovarian surface epithelial tumours is 16.53 ± 2.36

Table No 7: Comparison of Micro Vessel Density of Ovarian

Surface Epithelial Tumours

Type of Tumour	Mean MVD/HPF
Benign	4.48
Borderline	7.5
Malignant	16.5

NOTE: Mean Micro Vessel Density of malignant Ovarian Surface Epithelial Tumours (16.5) is high compared to benign (4.48) and borderline tumours (7.5)

Table No 8: Comparison of Micro Vessel Density between benign and malignant Ovarian Surface Epithelial tumours

Parameter	Benign Tumours	Malignant Tumours	P Value Student t Test
Mean of MVD/HPF	4.45	7.5	<0.001

NOTE: P value by Student t test is less than 0.001 indicating statistical significance of the study

DISCUSSION

Ovarian cancer is a malignancy with high mortality and aggressive course associated with poor prognosis in majority of the patients. The aim of the present study was to evaluate the microvessel density and compare it across a spectrum of ovarian surface epithelial tumours ranging from benign to malignant. The result obtained were reviewed in the light of other publications.

Our study revealed serous tumours to be the commonest (56%) similar to studies of Hollingsworth et al²¹, Arjunan et al¹³, Sehgal et al²². Abulafia et al²³ studied angiogenesis on ovarian tumours in 83 patients by calculating microvessel density using antibodies against vWF. Study showed that angiogenic switch occurs between benign and borderline and malignant tumours and microvessel density might help to differentiate between benign and invasive tumours. Wang et al²⁴ did a study on characteristics of contrast enhanced ultrasound and its utility in assessing microvessel density in ovarian tumours which showed that microvessel density is higher in malignant tumours as compared to benign. Sehgal et al²² conducted a study on 42 cases of ovarian surface epithelial tumours. Microvessel density was calculated using antibodies against CD 34. Results showed that malignant tumours showed higher microvessel density as compared to benign ovarian tumours and similar findings were obtained in our study. In our study 8 cases of borderline surface epithelial tumours were diagnosed; 4 each of serous and mucinous type. In these borderline tumours, the microvessel density was found to be higher than benign tumours and lower than malignant tumours.

The idea of neo-angiogenesis in solid tumour provided an impetus for development of therapeutic agents that block angiogenesis. Role of angiogenesis in ovarian carcinoma was uncertain until Hollingsworth et al²¹ study suggested that the degree of neovascularization is a useful prognostic factor which determines disease free survival. Our study concluded that average microvessel density was significantly higher in malignant ovarian surface epithelial tumours and high microvessel density was associated with transformation and acquisition of invasive phenotype of advanced epithelial ovarian cancers. Studies done by Hollingsworth et al²¹ and Arjunan et al¹³ corroborate our findings.

Ogawa et al²⁵ study using antibodies to CD34 in surface epithelial tumours of ovary showed that microvessel density is an independent prognostic factor. Rossochacka-Rostalska²⁶ study using antibodies to CD31 and CD34 in ovarian carcinomas and Van Diest et al²⁷ study in advanced epithelial ovarian cancer showed that increased microvessel density is associated with bad prognosis. Gasparini et al²⁸ reported that microvessel density is the most significant predictor of metastasis of breast carcinoma.

Table No 9: Supporting Studies of Micro Vessel Density

Study	Sample size	Mean MVD / hpf - Benign	Mean MVD / hpf - Malignant	P value
Present study	50	4.48 / 0.196 mm2	16.53 / 0.196 mm2	< 0.001
Sehgal et al ⁴⁹	42	16.53/ 0.375 mm2	34.5/ 0.375 mm2	< 0.001
Arjunan et al ¹⁴	50	14.88/ 0.375 mm2	26.09/ 0.375 mm2	0.002

Anti-angiogenic therapy is a very exciting and promising new

treatment modality for advanced ovarian cancers and is being used as frontline therapy for aggressive malignant surface epithelial ovarian cancers currently^{17,18,19}. Bevacizumab, a humanized anti-VEGF monoclonal antibody is the most widely studied drug. Novel approach of treatment of advanced ovarian cancers by using combination of Bevacizumab and other targeted drugs by modifying tumour microenvironment have led to improvement in 5 year survival rates¹⁶.

CONCLUSION

Microvessel density is useful in assessing the degree of angiogenesis in a tumour with high microvessel density being directly linked to local growth and distant metastasis. Our study concluded that microvessel density is an independent prognostic factor and a predictive tool for determining outcome in ovarian malignancy. In view of these results, new therapy should aim to alter the tumor microenvironment leading to decreased angiogenic capacity of tumour cells.

REFERENCES

1. Kumar, Abbas, Aster. The Female Genital Tract: Robbins and Cotran Pathologic Basis of Disease, South Asia Edition 9. Reed Elsevier; 2014. pg.1023-8.
2. Rekha, V.Kumar, Geetashree Mukherjee, Umadevi.K, Hazarika.D. Sclerosing stromal tumours of the ovary. Ind. Journal of cancer 1994;31:92-5.
3. Auersperg, N.; Wong, A.S.; Choi, K.C.; Kang, S. K.; Leung, P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 2001;22:255–88.
4. Levanon, K.; Crum, C.; Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 2008;26: 5284–93.
5. Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997;349:113-7.
6. Bamberg ES, Perrett CW. Angiogenesis in epithelial ovarian cancer. Mod Pathol 2002; 55:348-59.
7. Toi M, Kashitani J, Tominaga T. Tumour angiogenesis is an independent prognostic indicator of breast carcinoma. Int J Cancer 1993; 55:371-4.
8. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
9. Macchiarini P, Fontanini G, Hardin MJ, Blumfeld W, Folkman J. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 1992; 340:145-6.
10. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, Iki M. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 1966; 56:2671-6.
11. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1966; 78:226-31.
12. Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K, Muraoka R. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997; 57:1043-6.
13. A.Arjunan, G.S. Thiriveni Balaji. Expression of p53 and CD34 in surface epithelial tumours of ovary. IOSR-JDMS 2016;15:01-13
14. Matulonis UA: Bevacizumab and its use in epithelial ovarian cancer. Future Oncol 2011;7:365–79.
15. Collinson, F.; Jayson, G. New therapeutic agents in ovarian cancer. Curr. Opin. Obstet Gynecol. 2009; 21:44–53.
16. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30.
17. Burger RA, Sill M, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2005;23:457s, (suppl; abstr5009)
18. Garcia AA, Oza AM, Hirte H, et al: Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J Clin Oncol 23:455s, 2005(suppl; abstr 5000).
19. Cohn DE, Valmadre S, Resnick KE, et al: Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006;102:134-9.
20. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324(1):1-8.
21. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML and Merino MJ: Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995;147:33-41.
22. Sehgal, Shelly & Goyal, Prashant & Agarwal, Reena & Singh, Sompal & Kumar, Awanindra & Gupta, Ruchika & Kumar, Vinita & Agrawal, Dipti. Differences in the Angiogenesis of Benign and Malignant Surface Epithelial Ovarian Tumors Demonstrated by Microvessel Density and Immunohistochemistry. Journal of Interdisciplinary Histopathology. 2013;1(3). 145-52.
23. Abulafia O, Ruiz JE, Holcomb K, et al. Angiogenesis in early-invasive low-malignant-potential epithelial ovarian carcinoma. Obstet Gynecol 2000; 95:548–52.
24. Wang J, Lv F, Fei X, Cui Q, Wang L, Gao X, Yuan Z, Lin Q, Lv Y, Liu A. Study on characteristics of contrast enhanced ultrasound and its utility in assessing microvessel density in ovarian tumors or tumor like conditions. Int J BiolSci 2011; 7:600-6.
25. Ogawa S, Kaku T, Kobayashi H, et al. Prognostic significance of micro vessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 2002;176:111–8.
26. Rosschacka-Rostalska B, Gisterek JJ, Suder E, Szlachowska JK, Matkowski RA, Lacko A, Kornafel JA. Prognostic significance of microvessel density in ovarian cancer. Wiad Lek 2007; 60:129-37.
27. Van Diest PJ, Zeveing PJ, Zeveing LC, et al. Prognostic value of microvessel quantitation in cisplatin treated FIGO 3 and 4 ovarian cancer patients. Pathol Res Pract 1995;191:25–30.
28. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Maqubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node negative breast carcinoma. J Clin Oncol 1994, 12(3):441-3.